BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30584073)

  • 1. Direct Targeting of
    Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
    Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
    Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
    Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m
    Yang Y; Zhang Y; Chen G; Sun B; Luo F; Gao Y; Feng H; Li Y
    J Exp Clin Cancer Res; 2024 May; 43(1):141. PubMed ID: 38745192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.
    Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958555
    [No Abstract]   [Full Text] [Related]  

  • 5. A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma.
    Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM
    Oncogene; 2021 Apr; 40(13):2367-2381. PubMed ID: 33658627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is MYCN Overexpression Associated With Poor Outcome in
    Andrews A; Terry J
    Pediatr Dev Pathol; 2024; 27(3):282-283. PubMed ID: 38360554
    [No Abstract]   [Full Text] [Related]  

  • 7. Ceftriaxone exerts antitumor effects in MYCN-driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression.
    Chittavanich P; Saengwimol D; Roytrakul S; Rojanaporn D; Chaitankar V; Srimongkol A; Anurathapan U; Hongeng S; Kaewkhaw R
    Mol Oncol; 2024 Apr; 18(4):918-938. PubMed ID: 37975412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the relationship between MYCN gene and serum NSE and urinary VMA levels and neuroblastoma pathological features and prognosis.
    Zhang H; He X; Miao Q; Li L; Song J; Jiang X
    Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):134-139. PubMed ID: 38678619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Author(s)' Reply: Is MYCN Overexpression Associated With Poor Outcome in
    Zhao M; Shu Y; Gu W; Tang H; Mao J
    Pediatr Dev Pathol; 2024; 27(3):284-285. PubMed ID: 38360532
    [No Abstract]   [Full Text] [Related]  

  • 10. MYCN amplification and ATRX mutations are incompatible in neuroblastoma.
    Zeineldin M; Federico S; Chen X; Fan Y; Xu B; Stewart E; Zhou X; Jeon J; Griffiths L; Nguyen R; Norrie J; Easton J; Mulder H; Yergeau D; Liu Y; Wu J; Van Ryn C; Naranjo A; Hogarty MD; Kamiński MM; Valentine M; Pruett-Miller SM; Pappo A; Zhang J; Clay MR; Bahrami A; Vogel P; Lee S; Shelat A; Sarthy JF; Meers MP; George RE; Mardis ER; Wilson RK; Henikoff S; Downing JR; Dyer MA
    Nat Commun; 2020 Feb; 11(1):913. PubMed ID: 32060267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice.
    Stermann A; Huebener N; Seidel D; Fest S; Eschenburg G; Stauder M; Schramm A; Eggert A; Lode HN
    Cancer Immunol Immunother; 2015 Oct; 64(10):1215-27. PubMed ID: 26076666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MCPIP1 ribonuclease can bind and cleave
    Nowak I; Boratyn E; Student S; Bernhart SF; Fallmann J; Durbas M; Stadler PF; Rokita H
    RNA Biol; 2021 Jan; 18(1):144-156. PubMed ID: 32757706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Dysregulation in
    Epp S; Chuah SM; Halasz M
    Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of Aurora-A and ATR kinase results in regression of
    Roeschert I; Poon E; Henssen AG; Garcia HD; Gatti M; Giansanti C; Jamin Y; Ade CP; Gallant P; Schülein-Völk C; Beli P; Richards M; Rosenfeldt M; Altmeyer M; Anderson J; Eggert A; Dobbelstein M; Bayliss R; Chesler L; Büchel G; Eilers M
    Nat Cancer; 2021 Mar; 2(3):312-326. PubMed ID: 33768209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma.
    Choo Z; Koh X; Wong MRE; Ashokan RM; Ali Ahamed NSB; Kang C; Kuick CH; Chang KTE; Larisch S; Loh AHP; Chen ZX
    Cancer Res Commun; 2023 Nov; 3(11):2386-2399. PubMed ID: 37874199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroblastoma and Glioblastoma Cases With Amplified Oncogenes Have Reduced Numbers of Tumor-Resident Adaptive Immune Receptor Recombinations.
    Dabkowski TR; Varkhedi M; Song JJ; Gozlan EC; Blanck G
    JCO Precis Oncol; 2023 Sep; 7():e2300057. PubMed ID: 38085056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infantile mediastinal neuroblastoma presenting as an oncologic emergency: usefulness of serum-based
    Suematsu M; Yagyu S; Hosoi H; Iehara T
    BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34972781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MYCN 5' UTR as a therapeutic target in neuroblastoma.
    Volegova MP; Brown LE; Banerjee U; Dries R; Sharma B; Kennedy A; Porco JA; George RE
    Cell Rep; 2024 Apr; 43(5):114134. PubMed ID: 38662542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional TET2 gene polymorphisms increase the risk of neuroblastoma in Chinese children.
    Lin L; Wang B; Zhang X; Deng C; Zhou C; Zhu J; Wu H; He J
    IUBMB Life; 2024 Apr; 76(4):200-211. PubMed ID: 38014648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the mRNA-Binding Protein IGF2BP1 Suppresses Proliferation and Sensitizes Neuroblastoma Cells to Chemotherapeutic Agents.
    Biegel JM; Dhamdhere M; Gao S; Gowda CP; Kawasawa YI; Spiegelman VS
    Front Oncol; 2021; 11():608816. PubMed ID: 33796454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.